
|Videos|September 26, 2017
Dr. Alberts Discusses Updates in Liver Cancer
Author(s)Steven R. Alberts, MD
Steven R. Alberts, MD, professor of oncology in the College of Medicine, Mayo Clinic, discusses recent updates in liver cancer.
Advertisement
Steven R. Alberts, MD, professor of oncology in the College of Medicine, Mayo Clinic, discusses recent updates in liver cancer.
Until the approval of regorafenib (Stivarga) in 2017, the only FDA-approved agent for the treatment of hepatocellular carcinoma (HCC) was sorafenib (Nexavar).
At the 2017 ASCO Annual Meeting, data on lenvatinib (Lenvima) were presented, showing comparable results to sorafenib and is likely to be approved for patients with HCC, says Alberts.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
3
Hematology Experts Preview Key Abstracts to Watch at the 2026 Transplantation & Cellular Therapy Meetings
4
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
5



































